Skip to main content
  1. Market Insights
  2. Health
  3. Pharmaceuticals

Anti-Coagulants - Portugal

Portugal
  • In Portugal, the Anti-Coagulants market is expected to experience significant growth in the coming years.
  • By 2024, the projected revenue for this market is estimated to reach US$69.17m.
  • This growth is anticipated to continue, with an annual growth rate (CAGR 2024-2029) of 7.73%.
  • By 2029, the market volume is expected to reach US$100.40m.
  • When comparing the global market, it is worth noting that United States is projected to generate the highest revenue in the Anti-Coagulants market.
  • In 2024, the revenue from this market United States is estimated to be US$16.74bn.
  • Portugal is experiencing a growing demand for novel oral anticoagulants as an alternative to traditional warfarin therapy.

Definition:
The Anti-Coagulants market covers drugs that prevent blood from clotting, i.e., that prolong the clotting time. Anti-coagulants are certain types of antithrombotics, which are often also called blood thinners. Neither thrombolytic drugs, which dissolve clots after they have formed, nor other anti-thrombotics, such as antiplatetelet drugs, are covered in this market.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Bristol Myers Squibb, Bayer, Sanofi, Johnson & Johnson

In-Scope

  • Blood clotting inhibitors

Out-Of-Scope

  • Anti-fibrinolytics
  • Anti-hypertensives
  • Other hematology drugs
  • Other anti-thrombotic agents, such as platelet aggregation inhibitors
  • Thrombolytic drugs
Anti-Coagulants: market data & analysis - Cover

Market Insights report

Anti-Coagulants: market data & analysis

Study Details

    Revenue

    Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.

    Most recent update: Mar 2024

    Analyst Opinion

    The Anti-Coagulants market in Portugal has seen significant growth over the past few years.

    Customer preferences:
    Patients suffering from cardiovascular diseases in Portugal prefer anti-coagulants due to their effectiveness in preventing blood clots. Additionally, the aging population in the country has also contributed to the growth of the market as they are more prone to these diseases.

    Trends in the market:
    There has been a shift towards the use of direct oral anticoagulants (DOACs) in Portugal. This is due to their ease of use and reduced risk of bleeding compared to traditional anti-coagulants like warfarin. The market for DOACs has been growing rapidly as more patients are prescribed these drugs. Furthermore, there has been an increase in the number of patients diagnosed with atrial fibrillation, which has further driven the growth of the market.

    Local special circumstances:
    The healthcare system in Portugal is publicly funded, which means that the government plays a significant role in regulating the market. The government has been promoting the use of generic drugs to reduce healthcare costs, which has resulted in increased competition in the market. Additionally, there has been a rise in the number of pharmacies in the country, which has made it easier for patients to access these drugs.

    Underlying macroeconomic factors:
    The Portuguese economy has been recovering from the global financial crisis, which has resulted in increased healthcare spending. This has provided a boost to the anti-coagulants market as more patients are able to afford these drugs. Additionally, Portugal is a popular retirement destination for Europeans, which has resulted in an aging population and an increase in the number of patients suffering from cardiovascular diseases.

    Global Comparison

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

    Modeling approach / Market size:

    Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

    Health

    Access more Market Insights on Health topics with our featured report

    Anti-Coagulants: market data & analysis - BackgroundAnti-Coagulants: market data & analysis - Cover

    Key Market Indicators

    Notes: Based on data from IMF, World Bank, UN and Eurostat

    Most recent update: Sep 2024

    Source: Statista Market Insights

    Explore more high-quality data on related topic

    Global pharmaceutical industry - statistics & facts

    The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.
    More data on the topic

    Contact

    Get in touch with us. We are happy to help.